Mapping Markush

Barth, 2016, A novel concept for the search and retrieval of the Derwent Markush resource database, J. Chem. Inf. Model., 56, 821, 10.1021/acs.jcim.6b00082 Berks, 2001, Current state of the art of Markush topological search systems, World Patent Inf., 23, 5, 10.1016/S0172-2190(00)00108-3 Bessen, 2008 Bone, 2008, Markush under threat: US pto considers alternatives, Ind. Biotechnol., 4, 246, 10.1089/ind.2008.4.246 Braga, 2018, The role of specification in patent applications: a comparative study on sufficiency of disclosure, World Patent Inf., 53, 58, 10.1016/j.wpi.2018.05.008 Burdon, 2003, The art of using secondary patents to improve protection, J. Med. Mark., 3, 226, 10.1057/palgrave.jmm.5040125 Cohen, 2000, Protecting their intellectual assets: Appropriability conditions and why us manufacturing firms patent (or not) Correa, 2008, Guidelines for the examination of pharmaceutical patents: developing a public health perspective Cox, 1984 Crum-Brown, 1865, The connection of chemical constitution and physiological action, Trans. R. Soc. Edinb., 25, 257 Dhulap, 2019, Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation, Pharm. Patent Anal., 8, 91, 10.4155/ppa-2019-0014 Ellery, 2012 EuropeanCommission Federal-Register, 2007 Fitt, 2010, Selection patents and Markush claims in Europe, Biotechnol. Law Rep., 29, 17, 10.1089/blr.2010.9990 Frakes, 2019, Irrational ignorance at the patent office, Vanderbilt Law Rev., 72, 975 Gaessler, 2022, Patents, data exclusivity, and the development of new drugs, Rev. Econ. Stat., 104, 571, 10.1162/rest_a_00987 Galande, 2000, Combinatorial technology: an overview, Indian J. Pharm. Sci., 62, 84 Gambardella, 2008, The value of european patents, Eur. Manag. Rev., 5, 69, 10.1057/emr.2008.10 Grimpe, 2014, Resource complementarity and value capture in firm acquisitions: the role of intellectual property rights, Strateg. Manag. J., 35, 1762, 10.1002/smj.2181 Guellec, 2012, Pre-emptive patenting: securing market exclusion and freedom of operation, Econ. Innov. New Technol., 21, 1, 10.1080/10438599.2010.536378 Guerrini, 2013, Defining patent quality, Fordham Law Rev., 82, 3091 Gupta, 2020, One Product Hall, 2004, Prospects for improving us patent quality via postgrant opposition, Innov. Policy Econ., 4, 115, 10.1086/ipe.4.25056163 Hall, 2005, Market value and patent citations, RAND J. Econ., 36, 16 Harhoff, 1999, Citation frequency and the value of patented inventions, Rev. Econ. Stat., 81, 511, 10.1162/003465399558265 Harhoff, 2004, Determinants of opposition against epo patent grants-the case of biotechnology and pharmaceuticals, Int. J. Ind. Organ., 22, 443, 10.1016/j.ijindorg.2004.01.001 Harhoff, 2016, Conflict resolution, public goods, and patent thickets, Manag. Sci., 62, 704, 10.1287/mnsc.2015.2152 Harhoff, 2009, The duration of patent examination at the European patent office, Manag. Sci., 55, 1969, 10.1287/mnsc.1090.1069 Hemphill, 2011, When do generics challenge drug patents?, J. Empir. Leg. Stud., 8, 613, 10.1111/j.1740-1461.2011.01235.x Hemphill, 2012, Evergreening, patent challenges, and effective market life in pharmaceuticals, J. Health Econ., 31, 327, 10.1016/j.jhealeco.2012.01.004 Hilbe, 2011 Holman, 2017, In defense of secondary pharmaceutical patents: a response to the un's guidelines for pharmaceutical patent examination, Indiana Law Rev., 50, 759, 10.18060/4806.1153 Howard, 2007, Use of patents in drug lifecycle management, J. Generic Med., 4, 230, 10.1057/palgrave.jgm.4950065 Hughes, 2011, Principles of early drug discovery, Br. J. Pharmacol., 162, 1239, 10.1111/j.1476-5381.2010.01127.x Kalbfleisch, 2011 Kapczynski, 2012, Polymorphs and prodrugs and salts (oh my!): an empirical analysis of “secondary” pharmaceutical patents, PLoS ONE, 7, 10.1371/journal.pone.0049470 Karshtedt, 2021, The death of the genus claim, Harvard J. Law Tech., 35 Krieger, 2022, Missing novelty in drug development, Rev. Financ. Stud., 35, 636, 10.1093/rfs/hhab024 Kyle, 2016, Competition law, intellectual property, and the pharmaceutical sector, Antitrust Law J., 81, 1 Magerman, 2010, Exploring the feasibility and accuracy of latent semantic analysis based text mining techniques to detect similarity between patent documents and scientific publications, Scientometrics, 82, 289, 10.1007/s11192-009-0046-6 Mann, 2012, A new look at patent quality: relating patent prosecution to validity, J. Empir. Leg. Stud., 9, 1, 10.1111/j.1740-1461.2011.01245.x Marco, 2019, Patent claims and patent scope, Res. Policy, 48, 10.1016/j.respol.2019.04.014 Martin, 1995, Measuring diversity: experimental design of combinatorial libraries for drug discovery, J. Med. Chem., 38, 1431, 10.1021/jm00009a003 Merges, 1990, On the complex economics of patent scope, Columbia Law Rev., 90, 839, 10.2307/1122920 Michel, 2001, Patent citation analysis. A closer look at the basic input data from patent search reports, Scientometrics, 51, 185, 10.1023/A:1010577030871 Newall, 1996, Software: putting structures in a database, Anal. Chem., 68, 554A, 10.1021/ac962056a Prajapati, 2012, Product lifecycle management in pharmaceuticals, J. Med. Market., 12, 150, 10.1177/1745790412445292 Prior, 2012, The uspto's historic struggle with markush claims: will the 2011 guidelines provide relief?, 114 Putnam, 1996 Risch, 2007, The failure of public notice in patent prosecution, Harv. J. Technol. Law, 21, 179 Rogers, 2014, Federal circuit's obviousness test for new pharmaceutical compounds: gobbledygook, Chicago-Kent J. Intell. Prop., 14, 49 Rollins, 1985, 35 usc 119-description and enablement requirements, J. Patent Trademark Office Soc., 67, 386 Schmoch, 2008, Concept of a technology classification for country comparisons Scotchmer, 1991, Standing on the shoulders of giants: cumulative research and the patent law, J. Econ. Perspect., 5, 29, 10.1257/jep.5.1.29 Simmons, 1991, The grammar of Markush structure searching: vocabulary vs synthax, J. Chem. Inf. Comput. Sci., 31, 45, 10.1021/ci00001a007 Simmons, 2003, Markush structure searching over the years, World Patent Inf., 25, 195, 10.1016/S0172-2190(03)00073-5 Sleigh, 2010, Repurposing strategies for therapeutics, Pharm. Med., 24, 151, 10.1007/BF03256811 Sternitzke, 2013, An exploratory analysis of patent fencing in pharmaceuticals: the case of pde5 inhibitors, Res. Policy, 42, 542, 10.1016/j.respol.2012.11.003 Tokuno, 1993, Comparison of Markush structure databases, J. Chem. Inf. Comput. Sci., 33, 799, 10.1021/ci00016a001 Trajtenberg, 1990, A penny for your quotes: patent citations and the value of innovations, RAND J. Econ., 21, 172, 10.2307/2555502 van Pottelsberghe de la Potterie, 2008, A brief history of space and time: The scope-year index as a patent value indicator based on families and renewals, Scientometrics, 75, 10.1007/s11192-007-1864-z von Graevenitz, 2013, Incidence and growth of patent thickets - the impact of technological opportunities and complexity, J. Ind. Econ., 61, 521, 10.1111/joie.12032 Wagner, 2009, Understanding patent-quality mechanisms, Univ. Pa. Law Rev., 157, 2135 Wagner, 2016, What do patent-based measures tell us about product commercialization? Evidence from the pharmaceutical industry, Res. Policy, 45, 1091, 10.1016/j.respol.2016.02.006 Wegner, 1992 Wyld, 2009, High court considers Markush claims and the doctrine of UK selection patents, J. Intell. Prop. Law Pract., 4, 147 Zeman, 2008, Chemical selection inventions in the Epo and Germany: continued divergence in legal interpretation, Biotechnol. Law Rep., 27, 293, 10.1089/blr.2008.9936